tirzepatide surmount 5 Understanding SURMOUNT-5 trial about using Mounjaro & Wagevovy/Ozempic for weight loss in patients without Tirzepatide superior to Semaglutide- SURMOUNT-5

RNA sequencing of treated tumor samples reveals significant downregulation of genes associated with glycolysis, including GLUT1, HK2, and LDHA

These patients should be followed more closely ( Table 1 )

Upadhyay, 2024

Diagnosis rate impact by condition among female GLP-1 utilizers of Mounjaro, Ozempic, Wegovy, and Zepbound during first 24 months compared to control Note: All comparisons are at a 99% confidence interval Inpatient admission by condition among female GLP-1 utilizers of Mounjaro, Ozempic, Wegovy, and Zepbound during first 24 months compared to control Note: All comparisons are at a 99% confidence interval The Importance of Adherence Across both diabetes and weight loss cohorts, adherence to GLP-1 therapy at 80% or higher amplifies cost benefits